Simon Lykkemark

Simon Lykkemark

Auto-generated profile, based on publicly available information

Simon Lykkemark

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2014 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
YYYue Yu
Yue Yu
HWHui Wen
Hui Wen
JMJingyun Ma
Jingyun Ma
SLSimon Lykkemark
Simon Lykkemark
HXHui Xu
Hui Xu
QJQin Jianhua
Qin Jianhua

1 May 2015 in Drug Discovery Today
Verified
Journal Article
Closed access
NNNatalia Nuñez-Prado
Natalia Nuñez-Prado
MCMarta Compte
Marta Compte
SHSeandean Harwood
Seandean Harwood
AÁAna Álvarez-Méndez
Ana Álvarez-Méndez
SLSimon Lykkemark
Simon Lykkemark
LALuis Alvarez-Vallina
Luis Alvarez-Vallina

8 October 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OMOle Aalund Mandrup
Ole Aalund Mandrup
NFNiels Anton Friis
Niels Anton Friis
SLSimon Lykkemark
Simon Lykkemark
JJJesper Just
Jesper Just
Peter KristensenPeter Kristensen
Peter Kristensen
Today a number of synthetic antibody libraries of different formats have been created and used for the selection of a large number of recombinant antibodies. One of the determining factors for successful isolation of recombinant antibodies from libraries lies in the quality of the libraries i.e. the number of correctly folded, functional antibodies contained in the library. Here, we describe the construction of a novel, high quality, synthetic single domain antibody library dubbed Predator. The library is based on the HEL4 domain antibody with the addition of recently reported mutations concerning the amino acid composition at positions critical for the folding characteristics and aggregation propensities of domain antibodies. As a unique feature, the CDR3 of the library was designed to mimic the natural human immune response by designating amino acids known to be prevalent in functional antibodies to the diversity in CDR3. CDR randomizations were performed using trinucleotide synthesis to avoid the presence of stop codons. Furthermore a novel cycle free elongation method was used for the conversion of the synthesized single stranded DNA containing the randomized CDRs into double stranded DNA of the library. In addition a modular approach has been adopted for the scaffold in which each CDR region is flanked by unique restrictions sites, allowing easy affinity maturation of selected clones by CDR shuffling. To validate the quality of the library, one round phage display selections were performed on purified antigens and highly complex antigen mixtures such as cultured eukaryotic cells resulting in several specific binders. The further characterization of some of the selected clones, however, indicates a reduction in thermodynamic stability caused by the inclusion the additional mutations to the HEL4 scaffold.

1 May 2015 in Trends in Biotechnology
Verified
Journal Article
Closed access
DSDavid Sánchez-Martín
David Sánchez-Martín
MSMorten Dræby Sørensen
Morten Dræby Sørensen
SLSimon Lykkemark
Simon Lykkemark
LSLaura Sanz
Laura Sanz
Peter KristensenPeter Kristensen
Peter Kristensen
LALuis Alvarez-Vallina
Luis Alvarez-Vallina

28 April 2015 in Small
Verified
Journal Article
Closed access
PDF file
XZXu Zhang
Xu Zhang
ZMZhaoxu Meng
Zhaoxu Meng
JMJingyun Ma
Jingyun Ma
YSYang Shi
Yang Shi
HXHui Xu
Hui Xu
QJQin Jianhua
Qin Jianhua

24 April 2023 in OncoImmunology
Verified
Journal Article
Open access
LRLaura Rubio-Pérez
Laura Rubio-Pérez
RLRodrigo Lázaro-Gorines
Rodrigo Lázaro-Gorines
SHSeandean L. Harwood
Seandean L. Harwood
MCMarta Compte
Marta Compte
RNRocío Navarro
Rocío Navarro
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
Immune checkpoint blockade (ICB) with antibodies has shown durable clinical responses in a wide range of cancer types, but the overall response rate is still limited. Other effective therapeutic modalities to increase the ICB response rates are urgently needed. New bispecific antibody (bsAb) formats combining the ICB effect and a direct action on cancer cells could improve the efficacy of current immunotherapies. Here, we report the development of a PD-L1/EGFR symmetric bsAb by fusing a dual-targeting tandem trimmer body with the human IgG1 hinge and Fc regions. The bsAb was characterized in vitro and the antitumor efficacy was evaluated in humanized mice bearing xenografts of aggressive triple-negative breast cancer and lung cancer. The IgG-like hexavalent bsAb, designated IgTT-1E, was able to simultaneously bind both EGFR and PD-L1 antigens, inhibit EGF-mediated proliferation, effectively block PD-1/PD-L1 interaction, and induce strong antigen-specific antibody-dependent cellular cytotoxicity activity in vitro. Potent therapeutic efficacies of IgTT-1E in two different humanized mouse models were observed, where tumor growth control was associated with a significantly increased proportion of CD8+ T cells. These results support the development of IgTT-1E for the treatment of EGFR+ cancers.